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Abstract 
Two 99mTc/Re complexes based on flavone and aurone were tested as potential 
probes for imaging -amyloid plaques using single photon emission computed 
tomography. Both 99mTc-labeled derivatives showed higher affinity for A(1-42) 
aggregates than did 99mTc-BAT. In sections of brain tissue from an animal model of AD, 
the Re-flavone derivative 9 and Re–aurone derivative 19 intensely stained -amyloid 
plaques. In biodistribution experiments using normal mice, 99mTc-labeled flavone and 
aurone displayed similar radioactivity pharmacokinetics. With additional modifications 
to improve their brain uptake, 99mTc complexes based on the flavone or aurone scaffold 
may serve as probes for imaging cerebral -amyloid plaques  
 
Key words: Alzheimer’s disease, -amyloid plaque, Tc-99m, single photon emission 
computed tomography (SPECT), imaging.  
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Alzheimer’s disease (AD) is a neurodegenerative disorder of the brain associated 
with irreversible cognititive decline, memory impairment, and behavioral changes. 
Currently, the only definitive confirmation of AD is by postmortem histopathological 
examination of -amyloid plaques in the brain. The early appraisal of clinical symptoms 
for a diagnosis of AD is often difficult and unreliable. Numerous reports suggest the 
accelerated accumulation of -amyloid plaques in the brain to be a key risk factor 
associated with AD. Consequently, the detection of individual -amyloid plaques in 
vivo by single photon emission tomography (SPECT) or positron emission tomography 
(PET) should improve the diagnosis of and also accelerate the discovery of effective 
therapeutic agents for AD1-4. Many PET/SPECT probes for imaging -amyloid based on 
Congo Red, thioflavin T, and DDNP have been reported. Among them, [11C]PIB5,6, 
[11C]SB-137,8, [18F]BAY94-91729,10, [11C]BF-22711, [18F]FDDNP12,13, [123I]IMPY14,16, 
and [18F]AV-4517,18 have been tested clinically and demonstrated potential utility.  
There are more SPECT scanners than PET imaging devices installed for routine clinical 
imaging, which provides a certain advantage to using SPECT imaging agents. Since 
SPECT is more valuable than PET in terms of routine diagnostic use, the development 
of more useful Aβ imaging agents for SPECT has been a critical issue. Although many 
radioiodinated SPECT imaging agents for detecting β-amyloid plaques have been 
reported, there are few reports on the development of 99mTc imaging agents. 
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99mTc (T1/2 = 6.01 h, 141 keV) has become the most commonly used radionuclide in 
diagnostic nuclear medicine for several reasons:  it is readily produced by an 
99Mo/99mTc generator, the gamma-ray energy it emits is suitable for detection, and its 
physical half-life is compatible with the biological localization and residence time 
required for imaging. Its ready availability, essentially 24 h a day, and easiness of use 
make it the radionuclide of choice. New 99mTc-labeled imaging agents will provide 
simple, convenient, and widespread SPECT-based imaging methods for detecting and 
eventually quantifying-amyloid plaques in living brain tissue.  
It has been reported that a dopamine transporter imaging agent, [99mTc]TRODAT-1, 
is useful to detect the loss of dopamine neurons in the basal ganglia associated with 
Parkinson’s disease. This is the first example of a 99mTc imaging agent that can 
penetrate the blood-brain barrier via a simple diffusion mechanism and localize at sites 
in the central nervous system. Based on this success, efforts were made to search for 
comparable 99mTc imaging agents that target binding sites on -amyloid plaques in the 
brain of AD patients. Several 99mTc-labeled imaging probes have been developed 
(Figure 1), but no clinical study of them has been reported19-22. 
Recently, we have reported that flavonoids including chalcone, flavone, and aurone 
serve as useful molecular scaffolds in the development of imaging agents for β-amyloid 
plaques in the brain23-28. Initially, we designed and synthesized four 99mTc-labeled 
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chalcone derivatives with monoamine-monoamide dithiol (MAMA) and 
bis-amino-bis-thiol (BAT) (Figure 1)29.  MAMA and BAT were selected as a chelation 
ligand taking into consideration the permeability of the blood-brain barrier, because 
they form an electrically neutral complex with 99mTc30. 99mTc-BAT-chalcone (n=3)  
(Figure 1) showed good uptake into and rapid clearance from the brain in addition to 
high affinity for β-amyloid plaques, indicating it may be a promising probe for the 
detection of β-amyloid plaques in the brain29. Based on the positive results, we decided 
to further develop new 99mTc imaging agents based on the flavonoid scaffold.  
In the present study, to develop more useful 99mTc imaging agents for the clinical 
diagnosis of AD, we synthesized two flavone and aurone derivatives with BAT as a 
chelation ligand. We then evaluated the biological potential of these compounds as 
probes by testing their affinity for A aggregates and -amyloid plaques in sections of 
brain tissue from Tg2576 mice and their uptake by and clearance from the brain in 
biodistribution experiments using normal mice. Also, we compared their usefulness as 
A imaging probes with a 99mTc-labeled chalcone derivative reported previously31. To 
our knowledge, this is the first time 99mTc/Re complexes based on flavone and aurone 
scaffolds have been proposed as probes for the detection of -amyloid plaques in the 
brain. 
The synthesis of the 99mTc/Re complexes based on flavone and aurone was outlined 
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in Schemes 1 and 2. The chelation ligand (BAT) were synthesized according to methods 
reported previously with some slight modifications (26).  The most useful method of 
preparing flavones is known as the Baker-Venkataraman transformation23. A 
hydroxyacetophenone was first converted into a benzoyl ester (1) which was then 
treated with a base, forming a 1,3-diketone (2). Treatment of this diketone with acid led 
to the generation of the desired flavone (3). The free amino derivative 4 was readily 
prepared from 3 by reduction with SnCl2 (92% yield). Conversion of 4 to the 
dimethylamino derivative 5 was achieved by a method reported previously (83% yield). 
5 was converted to 6 by demethylation with BBr3 in CH2Cl2 (40% yield). The reaction 
of dibromopentane with 6 produced the flavone derivative 7 with a trimethine group. 
Then, 7 was joined to Tr-Boc-BAT to generate 8 (the precursor of 99mTc/Re reaction). 
The target aurone derivatives were prepared as shown in Scheme 2. The synthesis of the 
aurone backbone was achieved via an Aldol reaction of benzofuranones with 
benzaldehydes using Al2O3. 5-Methozy-3-benzofuranone (14) was reacted with 
4-dimethybenzaldehyde in the presence of Al2O3 in chloroform at room temperature to 
form 15 in a yield of 92%. The precursor of the reaction with 99mTc/Re, 18, was 
obtained as described for the synthesis of the flavone derivative 8. After deprotection of 
the thiol groups in 8 and 18 in TFA and triethylsilane, the Re complexes (9 and 19) 
were prepared through a reaction with (PPh3)2ReOCl3. The corresponding 
99mTc 
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complexes, 10 ([99mTc]BAT-FL) and 20 ([99mTc]BAT-AR), were prepared by a ligand 
exchange reaction employing the precursor 99mTc-glucoheptonate (GH). The resulting 
mixture was analyzed by reversed-phase HPLC, showing that a single radioactive 
complex formed with radiochemical purity higher than 95% after purification by HPLC. 
The identity of the complex was established by comparative HPLC using the 
corresponding Re complexes as a reference (Table 1). The retention times for 
[99mTc]BAT-FL and [99mTc]BAT-AR on HPLC (radioactivity) were 11.1 and 16.6 min, 
respectively. The retention times of the corresponding Re complexes on HPLC (UV 
detection) were 9.5 and 14.6 min, respectively. 
In vitro binding experiments to evaluate the affinity of [99mTc]BAT-FL and 
[99mTc]BAT-AR for A(1-42) aggregates were carried out in solutions. The percent 
radioactivity of [99mTc]BAT-FL and [99mTc]BAT-AR bound to aggregates increased 
dependent on the dose of A(1-42), while [99mTc]BAT showed no marked affinity for 
the aggregates (Figure 2). At all concentrations of A aggregates, [99mTc]BAT-AR 
showed significantly greater affinity than [99mTc]BAT-FL. In these binding experiments, 
the non-specific binding of [99mTc]BAT-FL and [99mTc]BAT-AR was estimated at 
1.62-1.85%. The affinity of [99mTc]BAT-FL and [99mTc]BAT-AR was less than that of 
99mTc-labeled chalcone derivatives reported previously (Figure 1)31. The order in terms 
of strength of binding corresponded with that of radioiodinated flavonoids23-25, 
 Ono et al. 8/38
indicating that the scaffolds of the [99mTc]BAT complexes play an important role in the 
affinity for A aggregates. 
To confirm the affinity for -amyloid plaques in the mouse brain, 
neuropathological fluorescent staining with Re derivatives (9 and 19) was carried out 
using Tg2576 mouse brain sections (Figure 3). Many -amyloid plaques were clearly 
stained with the derivatives (Figure 3-A and B), as reflected by the high affinity for A 
aggregates in binding assays in vitro. The labeling pattern was consistent with that 
observed with thioflavin S (Figure 3-C and D). These results suggest that 
[99mTc]BAT-FL and [99mTc]BAT-AR would bind to -amyloid plaques in the mouse 
brain in addition to having affinity for synthetic A(1-42) aggregates. Although 
[99mTc]BAT-AR showed greater affinity than [99mTc]BAT-AR in the binding assays in 
vitro, no marked difference in binding between [99mTc]BAT-FL and [99mTc]BAT-AR 
was observed in the fluorescent staining experiments. 
 [99mTc]BAT-FL and [99mTc]BAT-AR were examined as to their biodistribution in 
normal mice (Table 2). A biodistribution study provides important information on brain 
uptake. The ideal probe for imaging -amyloid should penetrate the blood-brain barrier 
well enough to deliver a sufficient dose into the brain while clearing rapidly from 
normal regions so as to achieve a high signal to noise ratio in the AD brain. Previous 
studies suggest that the optimal lipophilicity for entry into the brain is obtained with log 
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P values of between 1 and 3. [99mTc]BAT-FL and [99mTc]BAT-AR had log P values of 
2.77 and 2.23, respectively (Table 1), but showed less uptake, 0.64 and 0.79 %ID/g at 2 
min postinjection, than expected. Thereafter, the radioactivity of [99mTc]BAT-FL and 
[99mTc]BAT-AR that accumulated in the brain was rapidly eliminated (0.23 and 
0.11%ID/g at 60 min postinjection). Recently, we have reported that the 99mTc-labeled 
chalcone derivative showed high uptake (1.48%ID/g at 2 min postinjection) into and 
rapid clearance (0.17%ID/g at 60 min postinjection) from the brain, a highly desirable 
property for imaging agents for -amyloid plaques29. The pharmacokinetics of the 
99mTc-labeled chalcone derivative in the brain appears superior to that of any 
99mTc-labeled probes reported previously, indicating that this compound should be 
investigated further as a potentially useful probe for imaging -amyloid. Compared with 
that of the 99mTc-labeled chalcone31, the radioactivity of [99mTc]BAT-FL and 
[99mTc]BAT-AR appears insufficient for the imaging of -amyloid plaques in the brain. 
Since the affinity of [99mTc]BAT-FL and [99mTc]BAT-AR for Aβ aggregates was as 
high as that of 99mTc-labeled chalcone derivatives29, improvement of the uptake of  
[99mTc]BAT-FL and [99mTc]BAT-AR is an important prerequisite to developing more 
useful 99mTc-labeled probes. Therefore, additional structural changes in the flavone and 
aurone scaffold are needed to further improve the pharmacokinetics of [99mTc]BAT-FL 
and [99mTc]BAT-AR in vivo.  
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In conclusion, we successfully designed and synthesized novel 99mTc/Re complexes 
based on flavone and aurone for the detection of -amyloid plaques in the brain. Both 
[99mTc]BAT-FL and [99mTc]BAT-AR showed high affinity for synthetic A(1-42) 
aggregates. In experiments in vitro using sections of brain from Tg2576 mice, 
Re-complexes intensely stained -amyloid plaques. In addition, [99mTc]BAT-FL and 
[99mTc]BAT-AR displayed good uptake into and a rapid washout from the brain after 
their injection in normal mice. This combination of affinity for -amyloid plaques, and 
good uptake and clearance makes [99mTc]BAT-FL and [99mTc]BAT-AR promising 
probes for the detection of -amyloid plaques in the brain, although additional 
modifications are required to enhance their uptake. The results of the present study 
should provide information useful for the development of 99mTc-labeled probes for the 
imaging of -amyloid plaques in the brain. 
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Table 1. HPLC retention times of 99mTc/Re compounds and log P of 99mTc compounds. 






Log P of 99mTc 
compoundsb 
9  9.5 10 11.1 2.77 ± 0.04 
19  14.6 20 16.6 2.23 ± 0.04 
aReversed-phase HPLC using a mixture of H2O-acetonitrile (2:3) as a mobile phase. 
bThe measurement was done in triplicate and repeated three times. Each value 
represents the mean ± SD for three independent experiments. 
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Table 2. Biodistribution of radioactivity after injection of [99mTc]FL and [99mTc]AR in 
normal micea. 
  Time after injection (min)  
Organ 2 10 30 60 
[99mTc]BAT-FL    
Blood 1.90 (0.08) 0.80 (0.16) 0.41 (0.06) 0.28 (0.06) 
Liver 19.35 (1.30) 24.75 (3.45) 27.73 (3.30) 24.12 (3.08) 
Kidney 9.70 (0.83) 5.56 (0.84) 2.38 (0.30) 1.40 (0.20) 
Intestine b 4.54 (0.42) 11.36 (1.88) 26.61 (3.93) 42 67 (2.98) 
Spleen 3.24 (0.61) 2.21 (0.31) 1.04 (0.42) 0.45 (0.07) 
Lung 11.42 (2.10) 3.84 (0.57) 1.70 (0.24) 1.07 (0.16) 
Stomach b 0.90 (0.15) 1.36 (0.55) 1.52 (0.67) 2.45 (1.04) 
Pancreas 4.41 (0.29) 4.31 (0.35) 1.89 (0.15) 0.84 (0.17) 
Heart 12.00 (1.16) 3.12 (0.51) 0.99 (0.18) 0.44 (0.09) 
Brain 0.64 (0.07) 0.57 (0.14) 0.36 (0.01) 0.23 (0.04) 
[99mTc]BAT-AR    
Blood 1.56 (0.16) 0.71 (0.07) 0.35 (0.04) 0.21 (0.04) 
Liver 17.76 (1.51) 17.77 (1.70) 15.17 (0.95) 12.96 (1.48) 
 Ono et al. 17/38
Kidney 11.50 (0.73) 8.77 (1.15) 4.83 (0.77) 3.28 (1.52) 
Intestine b 6.78 (0.78) 26.20 (2.45) 46.06 (3.17) 55.33 (7.42) 
Spleen 2.87 (0.30) 1.92 (0.47) 0.70 (0.07) 0.35 (0.15) 
Lung 6.10 (1.15) 3.25 (0.78) 1.63 (0.42) 0.85 (0.18) 
Stomach b 1.03 (0.13) 1.63 (0.25) 1.88 (0.11) 1.69 (0.49) 
Pancreas 5.85 (1.09) 4.20 (0.68) 1.53 (0.54) 0.60 (0.30) 
Heart 12.30 (1.21) 3.26 (0.43) 1.15 (0.30) 0.40 (0.09) 
Brain 0.79 (0.12) 0.70 (0.05) 0.27 (0.06) 0.11 (0.04) 
aEach value represents the mean (SD) for 3–6 mice at each interval. Expressed as % 
injected dose per gram. bExpressed as % injected dose per organ. 






























































































Scheme 1. Synthesis of flavone derivatives. 



































































































Scheme 2. Synthesis of aurone derivatives. 
 
 



































































n = 3 or 5
X = CH2 or C=O
 
Figure 1. Chemical structure of 99mTc-labeled A imaging probes reported previously. 
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Figure 2. Binding assay of [99mTc]BAT-FL, [99mTc]BAT-AR, and [99mTc]BAT with 
A(1-42) aggregates. Values are the mean ± standard error of the mean for three 
independent experiments. 




Figure 3. Fluorescent staining of the flavone derivative 9 (A), and aurone derivative 19 
(B) in Tg2576 mouse brain. Labeled plaques were confirmed by staining the adjacent 
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Experimental 
General 
All reagents were obtained commercially and used without further purification unless 
otherwise indicated. 1H NMR spectra were obtained on a Varian Gemini 300 
spectrometer with TMS as an internal standard. Coupling constants are reported in hertz. 
Multiplicity was defined by s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), 
and m (multiplet). Mass spectra were obtained on a JEOL IMS-DX. HPLC was 
performed with a Shimadzu system (a LC-10AT pump with a SPD-10A UV detector, 
λ= 254 nm) using a Cosmosil C18 (Nakalai Tesque, 5C18-AR-II, 4.6×150 mm) and 
acetonitrile/water (3/2) as the mobile phase delivered at a flow rate of 1.0 mL/min. The 
99mTc-chalcone derivative was synthesized according to a method reported previously. 
Compounds 9 and 19 were proven by this method to show >95% purity. 
 
Chemistry 
2-Acetyl-4-methoxyphenyl 4-nitrobenzoate (1). 
To a stirring solution of 2’-hydroxy-5’-methoxyacetophenone (1.66 g, 10 mmol) in 
pyridine (25 mL) was added 4-nitrobenzoyl chloride (1.86 g, 10 mmol). The reaction 
mixture was stirred at room temperature for 3 h, and poured into a 1 M aqueous HCl / 
ice solution with vigorous stirring. The precipitate that formed was filtered and washed 
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with water to yield acetophenone 2 (2.66 g, 85% yield). 1H NMR (300 MHz, CDCl3) δ 
2.54 (s, 3H), 3.89 (s, 3H), 7.14–7.16 (m, 2H), 7.38 (d, J = 2.7 Hz, 1H), 8.37 (s, 4H). 
 
1-(2-Hydroxy-5-methoxyphenyl)-3-(4-nitrophenyl)propane-1,3-dione (2). 
A solution of 1 (2.66 g, 8.45 mmol) and pyridine (25 mL) was heated to 50 , and 
pulverized potassium hydroxide (2.37 g, 42.3 mmol) was added. The reaction mixture 
was stirred for 90 min, and when it had cooled, a 10% aqueous acetic acid solution was 
added. The yellow precipitate that formed was filtered to yield 2 (2.08 g, 78% yield). 1H 
NMR (300 MHz, CDCl3) δ 3.85 (s, 3H), 6.84 (s, 1H), 6.99 (d, J = 8.7 Hz, 1H), 
7.14–7.18 (m, 1H), 7.22 (d, J = 3.0 Hz, 1H), 8.10 (d, J = 9.0 Hz, 2H), 8.35 (d, J = 9.3 
Hz, 2H), 11.50 (s, 1H). 
 
6-Methoxy-2-(4-nitrophenyl)-4H-chromen-4-one (3). 
A mixture of the diketone 2 (2.08 g, 6.59 mmol), concentrated sulfuric acid (2 mL), and 
glacial acetic acid (30 mL) was heated at 100  for 2 h and cooled to room temperature. 
The mixture was poured into cold water, and the resulting precipitate was filtered to 
yield 3 (1.98 g, 100%). 1H NMR (300 MHz, CDCl3) δ 3.92 (s, 3H), 6.91 (s, 1H), 
7.33–7.37 (m, 1H), 7.55 (d, J = 9.0 Hz, 1H), 7.61 (d, J = 3.0 Hz, 1H), 8.11 (d, J = 9.0 
Hz, 2H), 8.39 (d, J = 9.3 Hz, 2H). 
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2-(4-Aminophenyl)-6-methoxy-4H-chromen-4-one (4). 
A mixture of 3 (1.98 g, 6.67 mmol), SnCl2 (6.33 g, 33.4 mmol), and EtOH (20 mL) was 
stirred at 100  for 1 h. After the mixture had cooled to room temperature, 1 M NaOH 
was added until the solution became alkaline. After extraction with ethyl acetate, the 
combined organic layers were dried over Na2SO4 and filtered. The solvent was removed 
to give 1.63 g of 4 (92% yield). 1H NMR (300 MHz, CDCl3) δ 3.91 (s, 3H), 4.08 (s, 
broad, 2H), 6.70 (s, 1H), 6.76 (d, J = 9.0 Hz, 2H), 7.24–7.28 (m, 1H), 7.47 (d, J = 9.3 
Hz, 1H), 7.60 (d, J = 3.0 Hz, 1H), 7.75 (d, J = 9.0 Hz, 2H). 
 
2-(4-(Dimethylamino)phenyl)-6-methoxy-4H-chromen-4-one (5). 
To a mixture of 4 (1.63 g, 6.08 mmol) and paraformaldehyde (1.82 g, 60.8 mmol) in 
AcOH (25 mL) was added NaCNBH3 (1.91 g, 30.4 mmol) in one portion at room 
temperature. The resulting mixture was stirred at room temperature for 1.5 h, and the 
addition of 1 M NaOH was followed by extraction with CHCl3. The organic layer was 
dried over Na2SO4. The solvent was removed, and the residue was purified by silica gel 
chromatography (CHCl3 : MeOH = 49 : 1) to give 1.48 g of 5 (83% yield). 
1H NMR 
(300 MHz, CDCl3) δ3.08 (s, 6H), 3.91 (s, 3H), 6.71 (s, 1H), 6.76 (d, J = 9.0 Hz, 2H), 
7.23–7.27 (m, 1H), 7.47 (d, J = 9.3 Hz, 1H), 7.60 (d, J = 3.3 Hz, 1H), 7.82 (d, J = 9.3 
Hz, 2H). 
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2-(4-(Dimethylamino)phenyl)-6-hydroxy-4H-chromen-4-one (6). 
To a solution of 5 (905 mg, 3.06 mmol) in CH2Cl2 (20 mL) at 0 was added BBr3 (12 
mL, 1 M solution in CH2Cl2) dropwise in an ice bath. The mixture was allowed to warm 
to room temperature and stirred for 6 h. Water was added while the reaction mixture 
was cooled in an ice bath to keep the reaction temperature at 0. After the addition of a 
1 M aqueous HCl solution and extraction with CHCl3, the combined organic layers was 
dried over Na2SO4. The filtrate was concentrated and the residue was purified by silica 
gel chromatography (CHCl3 : MeOH = 20 : 1) to give 342 mg of 6 (40% yield). 
1H 
NMR (300 MHz, CDCl3) δ 3.08 (s, 6H), 6.69 (s, 1H), 6.76 (d, J = 9.3 Hz, 2H), 




To a solution of 6 (342 mg, 1.22 mmol) in acetonitrile (20 mL) were added 
1,3-dibromopropane (0.248 mL, 2.43 mmol) and K2CO3 (1 g). The reaction mixture was 
heated to reflux for 4 h. When the acetonitrile had evaporated, the residue was poured 
into a saturated NaCl solution. After extraction with CHCl3, the organic layer was 
combined and dried with Na2SO4. The mixture was concentrated, and purified by silica 
gel chromatography (CHCl3 : CH3OH = 199 : 1) to give 312 mg of 7 (64% yield). 
1H 
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NMR (300 MHz, CDCl3) δ 2.36 (q, J = 6.2 Hz, 2H), 3.07 (s, 6H), 3.62 (t, J = 6.6 Hz, 
2H), 4.22 (t, J = 5.9 Hz, 2H), 6.70 (s, 1H), 6.76 (d, J = 7.2 Hz, 2H), 7.22–7.30 (m, 1H), 
7.47 (d, J = 9.3 Hz, 1H), 7.61 (d, J = 3.0 Hz, 1H), 7.81 (d, J = 9.0 Hz, 1H). 
 
Compound 8 (Tr-BAT-C3-FL). 
To a solution of 7 (529 mg, 1.27 mmol) and Tr-Boc-BAT (847 mg, 1.11 mmol) in DMF 
(20 mL) was added DIPEA (2 mL). The reaction mixture was heated to reflux for 12 h. 
After the solvent had evaporated, the residue was purified by silica gel chromatography 
(using CHCl3 and then ethyl acetate : hexane of 1 : 1) to give 57 mg of 8 (5% yield). 
1H 
NMR (300 MHz, CDCl3) δ 1.37 (s, 9H), 1.71 (t, J = 6.5 Hz, 2H), 2.24–2.44 (m, 10H), 
2.84-3.00 (m, 4H), 3.07 (s, 6H), 3.96 (t, J = 6.0 Hz, 2H), 6.70 (s, 1H), 6.76 (d, J = 9.3 
Hz, 2H), 7.13–7.29 (m, 19H), 7.37–7.41 (m, 13H), 7.55 (d, J = 3.0 Hz, 1H), 7.82 (d, J = 
9.0 Hz, 2H). MS m/z 1086 (MH＋). 
 
Compound 10 (Re-BAT-FL). 
To a solution of 8 (49 mg, 0.045 mmol) in TFA (2 mL) was added triethylsilane (0.1 
mL) and mixed, and then the solvent was removed under a stream of nitrogen gas. The 
residue was resolved in a mixed solvent (22 mL, CH2Cl2:CH3OH = 10:1), was added 
(Ph3P)2ReOCl3 (75 mg, 0.090 mmol) and 1 M sodium acetate in methanol (4 mL). The 
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reaction mixture was heated to reflux for 6 h, after cooling to room temperature, mixed 
with ethyl acetate (60 mL) and filtered. Evaporation of the solvent gave a residue which 
was purified with silica gel chromatography (CHCl3 : CH3OH = 49 : 1), and then 
RP-HPLC (acetonitorile : H2O = 4 : 1) to give 15 mg (46%) of 10. 
1H NMR (300 MHz, 
CDCl3) δ 1.75–1.85 (m, 1H), 2.26–2.32 (m, 2H), 2.76–2.81 (m, 1H), 2.96–3.05 (m, 2H), 
3.08 (s, 6H), 3.24–3.49 (m, 4H), 3.75–3.98 (m, 3H), 4.17–4.39 (m, 5H), 6.71 (s, 1H), 
6.76 (d, J = 8.7 Hz, 2H), 7.23–7.28 (m, 1H), 7.50 (d, J = 9.3 Hz, 1H), 7.57 (d, J = 3.0 
Hz, 1H), 7.82 (d, J = 9.0 Hz, 2H). HRMS m/z C26H33N3O4ReS2 found 702.1489, calcd 
702.1470 (MH＋). 
 
Methyl 2-((ethoxycarbonyl)methoxy)-5-methoxybenzoate (11). 
To a solution of methyl 5-methoxysalicylate (1.49 mL, 10 mmol) in acetone (10 mL) 
were added K2CO3 (1 g) and ethyl bromoacetate (1.49 mL, 13.5 mmol). The mixture 
was stirred for 4 h under reflux. When the solvent had evaporated, the residue was 
dissolved in water. After extraction with ethyl acetate, the organic layer was dried over 
Na2SO4. Evaporation of the solvent gave 2.90 g of 11 (100%).
 1H NMR (300 MHz, 
CDCl3) δ 1.30 (t, J = 7.1 Hz, 3H), 3.80 (s, 3H), 3.91 (s, 3H), 4.26 (q, J = 7.1 Hz, 2H), 
4.65 (s, 2H), 6.92 (d, J = 9.0 Hz, 1H), 6.98–7.02 (m, 1H), 7.35 (d, J = 3.0 Hz, 1H). 
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2-(Carboxymethoxy)-5-methoxybenzoic acid (12). 
To a solution of 11 (2.90 g, 10.8 mmol) in methanol (10 mL) was added 10% aqueous 
KOH (10 mL). The mixture was stirred for 2 h at room temperature. The product 
formed by adding 1 M HCl was filtered to give 2.25 g of 12 (100%). 1H NMR (300 
MHz, CD3OD) δ 3.79 (s, 3H), 4.77 (s, 2H), 7.08 (s, 1H), 7.10 (d, J = 3.0 Hz, 1H), 7.41 
(d, J = 3.0 Hz, 1H). 
 
5-Methoxybenzofuran-3-yl acetate (13). 
A mixture of acetic anhydride (30 mL), acetic acid (6 mL), anhydrous sodium acetate 
(1.5 g), and 12 (865 mg, 3.82 mmol) was heated to reflux for 6 h. Water was added, and 
after extraction with ethyl acetate and drying of the organic layer over Na2SO4, the 
solvent was removed, and the residue was purified by silica gel chromatography (ethyl 
acetate : hexane = 1 : 4) to give 687 mg of 13 (87%). 
1H NMR (300 MHz, CDCl3) δ 
2.38 (s, 3H), 3.86 (s, 3H), 6.91–6.95 (m, 1H), 6.97 (d, J = 2.1 Hz, 1H), 7.34 (d, J = 9.0 
Hz, 1H), 7.98 (s, 1H). 
 
5-Methoxybenzofuran-3(2H)-one (14). 
A mixture of 13 (815 mg, 3.95 mmol), methanol (10 mL), water (5 mL), and 1 M HCl 
(2 mL) was heated to reflux for 5 h, and allowed to cool to room temperature. Water 
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was then added, and following extraction with CHCl3, the combined organic layers 
were dried over Na2SO4 and filtered. The solvent was removed to give 621 mg of 14 
(96%). 1H NMR (300 MHz, CDCl3) δ3.81 (s, 3H), 4.65 (s, 2H), 7.06 (s, 1H), 7.08 (d, J 
= 5.4 Hz, 1H), 7.24 (d, J = 3.0 Hz, 1H). 
 
(Z)-2-(4-(Dimethylamino)benzylidene)-5-methoxybenzofuran-3(2H)-one (15).  
To a solution of 14 (246 mg, 1.50 mmol) and 4-dimethylaminobenzaldehyde (224 mg, 
1.50 mmol) in EtOH (20 mL) was added Al2O3 (2.7 g). The mixture was stirred for 24 h 
at room temperature. After filtration of the reaction mixture, the solvent of the filtrate 
was removed, and the residue was purified by silica gel chromatography (ethyl acetate : 
hexane = 1 : 2) to give 405 mg of 15 (92%). 1H NMR (300 MHz, CDCl3) δ 3.08 (s, 6H), 




BBr3 (7 mL, 1 M solution in CH2Cl2) was added to a solution of 15 (405 mg, 1.37 
mmol) in CH2Cl2 (10 mL) dropwise in an ice bath. The mixture was allowed to warm to 
room temperature and stirred for 12 h. Water was added while the reaction mixture was 
cooled in an ice bath to keep the reaction temperature at 0. The mixture was poured 
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into a 1 M aqueous HCl solution and after extraction with CHCl3, the combined organic 
phase was dried over Na2SO4. The filtrate was concentrated and the residue was purified 
by silica gel chromatography (CHCl3 : MeOH = 20 : 1) to give 186 mg of 16 (48%). 
1H 
NMR (300 MHz, CD3OD) δ 3.08 (s, 6H), 6.81 (d, J = 9.3 Hz, 2H), 6.87 (s, 1H), 7.07 (d, 




To a solution of 16 (432 mg, 1.54 mmol) in acetonitrile (25 mL) were added 
1,3-dibromopropane (0.313 mL, 3.07 mmol) and K2CO3 (1 g). The reaction mixture was 
heated to reflux for 4 h. When the acetonitrile had evaporated, the residue was poured 
into a saturated NaCl solution. After extraction with CHCl3, the organic layer was 
combined and dried with Na2SO4. The mixture was concentrated, and purified by silica 
gel chromatography using CHCl3 to give 410 mg of 17 (66% yield). 
1H NMR (300 
MHz, CDCl3) δ 2.33 (q, J = 6.1 Hz, 2H), 3.05 (s, 6H), 3.61 (t, J = 6.5 Hz, 2H), 4.12 (t, J 
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Compound 18 (Tr-BAT-AR). 
To a solution of 17 (410 mg, 1.02 mmol) and Tr-Boc-BAT (728 mg, 0.952 mmol) in 
DMF (20 mL) was added DIPEA (0.4 mL). The reaction mixture was heated to reflux 
for 12 h. When the solvent had evaporated, a saturated NaCl solution was added and 
after extraction with CHCl3, the organic layers were combined and dried with Na2SO4. 
Evaporation of the solvent gave a residue which was purified by silica gel 
chromatography (using CHCl3 and then ethyl acetate : hexane of 1 : 2) to give 176 mg 
of 18 (16% yield). 1H NMR (300 MHz, CDCl3) δ1.38 (s, 9H), 1.69 (quin, J = 6.3 Hz, 
2H), 2.22–2.37 (m, 10H), 2.81–2.99 (m, 4H), 3.04 (s, 6H), 3.88 (t, J = 6.0 Hz, 2H), 6.73 
(d, J = 9.3 Hz, 2H), 6.90 (s, 1H), 7.12–7.28 (m, 21H), 7.36–7.41 (m, 12H), 7.83 (d, J = 
9.0 Hz, 2H). MS m/z 1086 (MH＋). 
 
Compound 20 (Re-BAT-AR). 
To a solution of 18 (54 mg, 0.050 mmol) in TFA (2 mL) was added triethylsilane (0.1 
mL) and mixed, and then the solvent was removed under a stream of nitrogen gas. The 
residue was resolved in a mixed solvent (22 mL, CH2Cl2:CH3OH = 10:1), and 
(Ph3P)2ReOCl3 (83 mg, 0.100 mmol) and 1 M sodium acetate in methanol (4 mL) were 
added. The reaction mixture was heated to reflux for 6 h, then cooled to room 
temperature. Ethyl acetate (60 mL) was added and the mixture was filtered. Evaporation 
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of the solvent gave a residue which was purified with silica gel chromatography 
(CHCl3 : CH3OH = 49 : 1), and then RP-HPLC (acetonitorile : H2O = 4 : 1) to give 10 
mg (29%) of 20. 1H NMR (300 MHz, CDCl3) δ 1.75–1.81 (m, 1H), 2.31–2.36 (m, 2H), 
2.76–2.81 (m, 1H), 2.96–3.04 (m, 2H), 3.08 (s, 6H), 3.25–3.49 (m, 4H), 3.78–3.90 (m, 
3H), 4.09–4.36 (m, 5H), 6.75 (d, J = 9.0 Hz, 2H), 6.93 (s, 1H), 7.20–7.29 (m, 3H), 7.84 
(d, J = 9.0 Hz, 2H). HRMS m/z C26H33N3O4ReS2 found 702.1442, calcd 702.1470 (MH
＋). 
 
99mTc labeling reaction. 
To a solution of sodium heptonate dehydrate (2 g, 7.04 mmol) in nanopure water (25 
µL) was added 0.75 µL of a SnCl2･2H2O solution [12 mg of Tin () chloride dehydrate 
(53.2 mmol) dissolved in 15 µL of 0.1 M HCl]. This solution was adjusted to pH 
8.5–9.0 using a small amount of 0.1 M NaOH, and then lyophilized to give Sn 
glucoheptonate (SnGH) kit. SnGH kit (1 mg) was added to a Na99mTcO4 solution (200 
µL) and reacted at room temperature for 10 min to give a 99mTcGH solution. To 
solutions of 8 and 18 (0.5 mg) in TFA (200 µL) was mixed in triethylsilane (10 µL), 
and mixed, and the solvents were removed under a stream of nitrogen gas. The residues 
were resolved in acetonitrile (200 µL), and 0.1 M HCl (15 µL) and the 99mTcGH 
solution (200 µL) were added. The reaction mixtures were heated to 80–90 ˚C for 10 
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min. After cooling to room temperature, the mixtures were purified with RP-HPLC to 
give [99mTc]BAT-FL and [99mTc]BAT-AR. [99mTc]BAT-FL and [99mTc]BAT-AR were 
analyzed by analytical RP-HPLC on a Cosmosil C18 column with an isocratic solvent of 
H2O/acetonitrile (2/3) at a flow rate of 1.0 mL/min. The absorption of the complexes 
was measured at 254 nm and the radioactivity of the 99mTc-labeled form was recorded 
for 30 min. 
 
Binding assays using the aggregated A peptide in solution 
A solid form of A(1–42) was purchased from Peptide Institute (Osaka, Japan). 
Aggregation was achieved by gently dissolving the peptide (0.25 mg/mL) in a buffer 
solution (pH 7.4) containing 10 mM sodium phosphate and 1 mM EDTA. The solution 
was incubated at 37 ˚C for 42 h with gentle and constant shaking. The binding assay 
was performed by mixing 50 µL of the A(1–42) aggregates (0–100 µg/mL), 50 µL of 
an appropriate concentration of the 99mTc-labeled form ([99mTc]BAT-FL and 
[99mTc]BAT-AR), and 900 µL of 30% ethanol in 12 × 75 mm borosilicate glass tubes. 
Nonspecific binding was defined in the presence of 1 µM of a chalcone derivative 
(4-dimethylamino-4’-iodo-chalcone). After incubation for 3 h at room temperature, the 
binding mixture was filtered through GF/B filters (Whatman, Kent, UK) using a M-24 
cell harvester (Brandel, Gaithersburg, MD). Filters containing the bound 99mTc-labeled 
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form were measured for radioactivity in a gamma counter (Perkin Elmer, WIZARD2 
2470). 
 
In vivo biodistribution in normal mice 
The experiments with animals were conducted in accordance with our institutional 
guidelines and approved by the Nagasaki University Animal Care Committee. A saline 
solution (100 µL) of radiolabeled agents (1.0×107 cpm/100 µL) containing ethanol (30 
µL) was injected intravenously directly into the tail of ddY mice (5 weeks old, 22–25 g). 
The mice were sacrificed at various time points postinjection. The organs of interest 
were removed and weighed, and radioactivity was measured with an automatic gamma 
counter (Perkin Elmer, WIZARD2 2470). 
 
Neuropathological staining of model mouse brain sections 
The Tg2576 transgenic mice (female, 30-month-old) were used as the Alzheimer’s 
model. After the mice were sacrificed by decapitation, the brains were immediately 
removed and frozen in powdered dry ice. The frozen blocks were sliced into serial 
sections, 10 mm thick. Each slide was incubated with a 50% EtOH solution (2.5-10 µM) 
of 10 and 20 for 2–9 h. The sections were washed in 50% EtOH for 5 min two times, 
and 10 was examined with excitation at 458 nm and 20 with excitation at 488 nm under 
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a microscope (Carl Zeiss, LSM710). Thereafter, the sections were stained with 
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